The Trump administration has selected five drugmakers as being most likely to develop a coronavirus vaccine, The New York Times reports.
According to the report, the five companies are Moderna, a partnership between Oxford University and AstraZeneca, Johnson & Johnson, Merck and Pfizer.
National Institute of Allergy and Infectious Diseases Director Anthony Fauci recently told a medical seminar “by the beginning of 2021 we hope to have a couple of hundred million doses.”
To read the full report on The New York Times, click here.
Click here to read Fierce Pharma’s coverage of the announcement.